Abstract and keywords
Introduction
Nonalcoholic fatty liver disease (NAFLD) closely correlated to obesity and insulin resistance is considered a hepatic manifestation of metabolic syndrome (Eguchi et al. 2006; Nehra et al. 2001 ).
Moreover, NAFLD describes a spectrum of lesions ranging from simple steatosis to steatosis combined with severe hepatic injury, such as in non-alcoholic steatohepatitis (NASH), which is characterized by cell death and inflammation. The prevalence of NAFLD has continued to increase worldwide, with about 10%
of patients initially diagnosed with NASH, which often progresses to end-stage liver diseases, such as cirrhosis or hepatocellular carcinoma. However, the exact molecular mechanisms of the pathogenesis of NAFLD remain unclear, while effective therapeutic and preventive strategies are limited (e.g., weightreducing nutritional regimens for overweight and obese subjects). Current research supports the "multiple-hit model" in the pathogenesis of NAFLD. As the "first hit," insulin resistance causes an increase in serum fatty acid (FA) concentrations and excess influx of FAs into the liver, resulting in simple steatosis (Tilg and Moschen 2010) . Lipotoxicity, such as direct lipid cytotoxicity, dysregulated hepatocyte apoptosis, and inflammation, and so on represents the "subsequent hit," which leads to hepatic dysfunction, resulting in progression to NASH (Tilg and Moschen 2010) . In particular, an increased FA supply to the liver has been strongly suggested to play a major role in hepatic lipotoxicity, as indicated by the close correlation between elevated serum FA concentrations and NAFLD severity (Nehra et al. 2001; Zhang et al. 2014) . Therefore, in vitro models of FA-overloaded conditions have been created using human hepatic cells to clarify the mechanisms of NAFLD pathogenesis (Chavez-Tapia et al. 2012 ;
visceral fat accumulation, which is known to be strongly associated with symptoms of metabolic syndrome, as described in a double-blind clinical trial (Ono et al. 2010) . As possible mechanisms, antiadipogenic actions on pre-adipocytes and cell lines, and lipolytic actions of LF on mature adipocytes have been suggested (Moreno-Navarrete et al. 2009; Ono et al. 2013; Ono et al. 2011; Yagi et al. 2008) . Also, LF reportedly improved plasma lipid profiles and hepatic triglyceride accumulation in an animal study of mice fed normal diets (Morishita et al. 2013; Takeuchi et al. 2004 ). Moreover, a recent study reported that LF administration exhibited beneficial effects on serum lipid profiles and hepatic triglyceride accumulation as the "first hit" in a high-fructose corn syrup-induced NAFLD model (Li and Hsieh 2014) .
In this report, it is also demonstrated that LF contributes to the inhibition of the hepatic inflammatory cytokines as a "subsequent hit" by scavenging lipopolysaccharides from the circulation. Although fructose directly enters the glycolytic pathway and causes an increase in hepatic-free FA accumulation, the effects of LF on the contribution of FA accumulation to NAFLD development have not been fully investigated. Therefore, the aim of this study was to clarify the direct effect of LF administration on a FAinduced in vitro model of NAFLD and identify the underlying mechanisms of LF.
Materials and Methods

Materials
Bovine LF was purchased from FrieslandCampina (Amersfoort, The Netherlands). According to the certificate of analysis, typical protein purity was 98%. Pepsin-digested LF (pdLF) was prepared as described previously (Ono et al. 2011 
Oil-red O staining
The cells were washed twice with ice-cold PBS and fixed in 10% formalin for 60 min. After fixation, the cells were stained with Oil-Red O solution for 15 min at room temperature. After staining, the cells were washed twice with distilled water. Intracellular lipid droplets were observed under a phase-contrast microscope.
Intracellular fat quantitation
Intracellular fat accumulation in HepG2 cells was quantified as reported previously (Avramoglu et al. 1995) . At 20 h after FAm treatment, cells were washed two times with 1 mL of ice-cold PBS and the intracellular lipids were extracted with 1 mL heptane-isopropanol (3:2, v/v) at room temperature for 30 min. Concentrated lipids were reconstituted in 2-propanol and the TG concentrations were analyzed using the Triglyceride E-Test Wako lipid assay kit (Wako Pure Chemical Industries, Ltd.). Cell protein was solubilized using 1 mL of 0.1 N NaOH and quantified by the Bradford method. 
Analysis of lipotoxicity-related outcomes
Western blot analysis
Whole cell lysates were prepared in lysis buffer (10 mM Tris, pH 7.4, 150 mM NaCl, 10 mM Na 4 P 2 O 7 ·10
H 2 O 1.0 mM EDTA, 1.0 mM EGTA, 0.5% Nonidet P-40, and 1% Triton-X) containing 0.2% protease inhibitors (Sigma-Aldrich) and 1% phosphatase inhibitors (Nacalai Tesque, Inc., Kyoto, Japan). The protein concentrations in the extracts were determined using the Bio-Rad Protein Assay kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Typically, 10-20 µg of protein from whole cell lysates were loaded on 8% sodium dodecyl sulfate-polyacrylamide electrophoresis gels. The separated proteins were transferred to an Immobilon-P membrane (EMD Millipore Corporation, Bedford, MA, USA), which was blocked for 1 h in blocking buffer (TBS with 0.05% Tween 20 containing 3% BSA), and then incubated with primary antibody diluted in TBS with 0.1% Tween 20 containing 5% BSA or at 4°C overnight.
After washing, the blot was incubated with the secondary antibody for 1 h in TBS buffer. Then, the membrane was washed and target protein images were captured using a Light-Capture instrument (AE-6981; ATTO Co., Ltd., Tokyo, Japan) with the ECL Western Blotting Detection System (GE Healthcare, Waukesha, WI, USA). Quantification of Akt and phospho-Akt immunoreactive areas was performed using a Light-Capture instrument. Primary antibodies were diluted to 1:1000 and secondary antibodies were diluted to 1:5000.
Statistical analysis
Data are presented as the means ± standard deviations. Basically, data were compared using one-way 
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Results
Effects of LF on cell viability and lipid accumulation in the FAm-induced NAFLD model
FAm treatment (1 mM) significantly decreased cell viability, whereas LF (100 µg/mL) simultaneously added with FAm recovered cell viability, but pdLF (100 µg/mL) did not (Fig. 1A ). Significant effects of LF on cell viability were observed at concentrations of 20-100 µg/mL (Fig. 1B) . Intracellular lipid accumulation of HepG2 cells was significantly increased by FAm treatment (Table 1) . LF had no effect on intracellular lipid accumulation. Microscopic observation confirmed that LF treatment (100 µg/mL) obviously inhibited the FAm-induced cell death without affecting the lipid accumulation (Fig. 1C , D and E).
Effect of LF on FAm-induced cytotoxicity and apoptosis
LDH activity and caspase-3/7 activity were significantly increased at 20 h after FAm treatment (Fig. 2) .
FAm-induced LDH activity was significantly inhibited by LF (5-100 µg/mL) in a dose-dependent manner.
The LF treatment (100 µg/mL) exhibited a 42% decrease in LDH activity compared with FAm-treated group, but didn't completely inhibit the FAm-induced LDH activity compared with no-treated group ( Fig.   2A ). The effect of LF on caspase-3/7 activity showed a similar result as that on LDH activity. However, caspase-3/7 activity was completely inhibited by 20 µg/mL LF treatment compared with no-treated group (Fig. 2C ). Since apoptosis induced by caspase-3 via the JNK signaling pathway was proposed to play a primary role in FAm-induced lipotoxicity, inhibition experiments were performed. SP600125 (50 µM), a JNK-specific inhibitor, exhibited significant inhibition of FAm-induced LDH and caspase-3/7 activities (Fig. 2B, D) . The results of the time-course analysis showed that FAm treatment significantly increased LDH activities at all-time points (2, 4, and 8 h) as compared to the untreated group (Fig. 3A) . LF significantly inhibited the increase in FAm-induced LDH activity at 4 h (21% decrease), but not at 2 and D r a f t 10 (46% decrease) (Fig. 3B) . JNK phosphorylation by FAm treatment didn't be detected at 2 and 4 h (data not shown), while FAm treatment slightly increased JNK phosphorylation at 8 h, as compared to the control group (Fig. S1A, B) . LF didn't inhibit FAm-induced JNK phosphorylation at 8 h.
Effect of LF on ER stress-induced cytotoxicity and apoptosis
HepG2 cells were treated with tunicamycin (2 and 10 µg/mL) to induce ER stress. As shown in Fig. 4A , cell viability was significantly decreased following treatment with tunicamycin at 10 µg/mL. In contrast to FAm treatment, LF did not recover cell viability. LDH and caspase-3/7 activities were significantly increased following tunicamycin treatment (10 µg/mL), whereas LF did not inhibit tunicamycin-induced LDH and capsase-3/7 activities ( Fig. 4B, C) .
Contribution of LF-induced Akt signaling to inhibition of lipotoxicity
Time-course analysis of Akt phosphorylation following LF treatment showed active Akt phosphorylation until 2 h after LF treatment ( 
Discussion
The results of the present study showed that LF directly inhibited FAm-induced lipotoxicity and recovered cell viability in the HepG2 NAFLD model (Fig. 1A , B, 2A and C), whereas pdLF exhibited no beneficial effect on cell viability (Fig. 1A) , suggesting that it was important for LF to reach the liver as an intact without digestion by pepsin. Several studies have reported the distribution of orally administered LF's distribution in rodents. Orally administered LF was detected in many tissues of mice and most abundantly detected in the liver by ELISA method (Fischer et al. 2007) . Moreover, it is reported that an 8-week regimen of oral LF administration (50-200 mg/kg/day) to high-fructose corn syrup-induced NAFLD mice induced a significant increase in LF accumulation in the liver (14.2 ± 1.7-22.8 ± 5.1 µg/g of liver) as well as impairment of NAFLD development (Li and Hsieh 2014). In the present study, we clarified that 5 µg/mL LF conveyed a significant beneficial effect against lipotoxicity (LDH and caspase-3/7 activities), but not lipid accumulation ( Fig. 2A , C and Table. 1). These results suggest that the attenuation of FAm-induced lipotoxicity by LF contributes to impairment of NAFLD development.
Besides, LF administration to mice for 4 weeks was reported to significantly decrease triglyceride concentrations in thoracic lymph fluid after feeding, suggesting that LF may inhibit triglyceride absorption by the small intestine (Takeuchi et al. 2004) . Taken together, the results of these reports suggest that oral administration of LF can potentially inhibit lipid accumulation as the "first hit" in the liver and impair the "subsequent hit," which promotes NAFLD development.
Regarding cytotoxicity (LDH activity) and apoptosis (caspase-3/7 activity), FAm treatment significantly increased LDH activity at 2 h and increased caspase-3/7 activity at 4 h, suggesting that cytotoxicity in the early time-course of the experiment was induced by FAm itself (Fig. 3A and B) . The inhibitory effect of LF on FAm-induced cytotoxicity until 8 h after FAm treatment was not as strong as that at 20 h ( Fig. 2A and 3A). Taken together, LF seems to inhibit both of the FAm-induced direct and apoptosis dependent cytotoxicity, but mainly inhibit the latter one. The results that LF completely inhibited FAm-induced caspase-3/7 activity, but not LDH activity (Fig. 3A, C) 
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). In the experiment using tunicamycin, LF failed to recover cell viability and inhibit lipotoxicity (Fig. 4A , B and C), strongly suggesting that LF inhibited the JNK signaling pathway, but not ER stressinduced signaling pathway and didn't inhibit caspase-3/7 activity itself by the interaction. Recently, it is Ogasawara et al. reported that LF directly scavenged ROS without a chelating effect (Ogasawara et al. 2014 ). However, in the present study, LF inhibited caspase-3/7 activity, but appeared not to inhibit JNK phosphorylation (Fig. 3B, Fig. S1 ), suggesting that the central mechanism of LF was different from that of ROS scavenging. and (E) FAm (1 mM) + LF (100 µg/mL). 
